BioCina
Neha Patel has extensive experience in the pharmaceutical and biotherapeutics sectors, currently serving as the Compliance and EHS (Interim) Lead and Sr Quality at BioCina since October 2021, a contract development and manufacturing organization specializing in recombinant biotherapeutics. Prior to BioCina, Neha worked at Pfizer in Manufacturing Quality from March 2016 to October 2021, and at Hospira, a Pfizer company, in Quality Assurance from October 2007 to March 2016. Neha also served as a Sr. Quality Assurance Officer at Unimed Technologies Limited from January 2005 to May 2007 and began in the industry as a Quality Assurance Officer at J.B. CHEMICALS & PHARMACEUTICALS LIMITED from July 2002 to December 2004.
This person is not in any teams
BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina’s first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME’s having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA and Health Canada. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. As one of the fastest growing companies in the biopharmaceutical industry across Australia, BioCina was awarded the 2024 South Australia “Emerging Business of the Year” award. Learn more at https://biocina.com.